CIMS Studienzentrum Bamberg GmbH

Research at CIMS Studienzentrum Bamberg focuses on atherosclerotic cardiovascular disease, heart failure, and hypercholesterolemia, aiming to lower lipid levels and reduce major adverse cardiac events through innovative therapies.

• Inclisiran for LDL‑cholesterol reduction
• Pelacarsen targeting lipoprotein(a)
• Vicadrostat combined with empagliflozin for heart failure
• Baxdrostat plus dapagliflozin to prevent heart failure events

The site conducts 21 clinical trials with a team of five investigators, advancing cardiovascular care in Europe.

Studies at the Bamberg center address obesity, overweight, and type 2 diabetes mellitus, evaluating therapies that improve metabolic health and sleep‑disordered breathing.

• Orforglipron for obstructive sleep apnea and weight management
• Eloralintide for body‑weight reduction and apnea‑hypopnea index improvement
• Tirzepatide versus dulaglutide on cardiovascular outcomes in diabetes
• Investigations of metabolic effects of novel weight‑loss agents

By integrating metabolic and respiratory research, the site supports comprehensive treatment strategies for patients with intertwined conditions.

The pulmonary department evaluates therapies for chronic obstructive pulmonary disease, asthma, bronchiectasis, and fibrotic lung disorders, seeking to improve lung function and reduce exacerbations.

• Triple inhaled therapy (BGF MDI) for COPD and severe asthma
• Astegolimab to lower COPD exacerbation rates
• BI 1015550 for progressive fibrosing interstitial lung diseases
• BI 1839100 targeting cough in idiopathic pulmonary fibrosis
• CHF6001 as add‑on for COPD exacerbation prevention
• Verekitug to enhance COPD control
• Tozorakimab as adjunct therapy for COPD
• BI 1291583 for bronchiectasis exacerbation reduction
• Benralizumab versus mepolizumab in eosinophilic granulomatosis with polyangiitis

With 21 active studies, the site contributes to advancing respiratory therapeutics across a range of chronic lung diseases.

Research explores immune modulation in conditions like severe asthma, EGPA, and COPD, testing biologics that target eosinophils and cytokine pathways to achieve better disease control.

• Benralizumab for eosinophil depletion in EGPA
• Mepolizumab comparison in refractory EGPA
• Astegolimab blocking IL‑33 signaling in COPD
• Tozorakimab targeting IL‑33/ST2 axis in COPD
• Novel agents influencing immune responses in pulmonary disease

The interdisciplinary approach at CIMS Studienzentrum Bamberg integrates immunology with cardiometabolic and respiratory research to develop holistic treatment options.